Targets › CASP9
3 programs from 2 companies in 6 trials: 6 Phase 1; Oncology; next expected readout May 2029.
Involved in the activation cascade of caspases responsible for apoptosis execution. Binding of caspase-9 to Apaf-1 leads to activation of the protease which then cleaves and activates effector caspases caspase-3 (CASP3) or caspase-7 (CASP7). (UniProt, P55211)
Open in Phaseline: the race on CASP9, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Baylor College of Medicine | AP1903 Caspase-9 activator/dimerizer drug that triggers apoptosis in iCaspase9-transduced T cells | CASP9 | Phase 1 | Acute Lymphoblastic Leukemia | May 2029 |
| Baylor College of Medicine | iCaspase9-transduced T cells Caspase-9 suicide gene-modified donor T cells for allogenic stem cell transplantation; iCa | CASP9 | Phase 1 | Acute Lymphoblastic Leukemia | May 2029 |
| Bellicum Pharmaceuticals | BPX-501 T cells (rivogenlecleucel) T cells transduced with CaspaCIDe safety switch (inducible caspase-9) | CASP9 | Phase 1 | Acute Lymphoblastic Leukemia; Leukemia; Hematologic Malignancy | Oct 2032 |
Acute Lymphoblastic Leukemia (4) Leukemia (1) Hematologic Malignancy (1)
mixed (3)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.